Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is they're positioning to capitalize on the unmet needs in other specific therapeutic areas, their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.
